title: A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda.
abstract: Integrated chemotherapy of neglected tropical diseases (NTD) through mass drug administration given as a single dose would increase treatment coverage and cost-effectiveness. This study reports on the safety of a combination of albendazole, ivermectin and praziquantel in the treatment of lymphatic filariasis (LF), schistosomiasis and soil-transmitted helminthiasis (STH) in infected children. In this randomised, controlled, single-blinded clinical trial conducted in 235 primary school children aged 5-18 years in Yumbe District in Northern Uganda, the triple combination therapy was compared with the current NTD programme regimen. Liver function testing was performed for all children who received combined therapy. The study included 48 children with LF alone, 60 children with schistosomiasis (Schistosoma mansoni), 41 children with STH, 49 children with schistosomiasis + LF and 37 children with all three types of infection. Children were closely monitored by a paediatrician for any adverse reactions for 7 days. No serious adverse events were experienced. However, 4 of 18 children in the test group and 2 of 3 children in the control group who did not report any ill conditions before treatment developed adverse drug reactions. The combined and conventional therapies were found to be equally safe. The efficacies of both therapies were comparable and satisfactory. [ClinicalTrials.gov identifier: NCT01050517].
authors.affiliation: Vector Control Division, Ministry of Health, P.O. Box 1661, Kampala, Uganda. harrietlwanga@ymail.com
authors.forename: Harriet
authors.initials: H
authors.lastname: Namwanje
authors.forename: Narcis
authors.initials: N
authors.lastname: Kabatereine
authors.forename: Annette
authors.initials: A
authors.lastname: Olsen
mesh_terms: D000293:Adolescent; D015766:Albendazole / Q000008:administration & dosage* / Q000191:economics; D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage* / Q000191:economics; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination / Q000379:methods; D004605:Elephantiasis, Filarial / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D005260:Female; D006373:Helminthiasis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage* / Q000191:economics; D008297:Male; D011223:Praziquantel / Q000008:administration & dosage* / Q000191:economics; D012552:Schistosomiasis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D018571:Sentinel Surveillance; D016037:Single-Blind Method; D016896:Treatment Outcome; D014454:Uganda / Q000453:epidemiology
chemical_list: D000977:Antiparasitic Agents; D011223:Praziquantel; D007559:Ivermectin; D015766:Albendazole